DK1713813T3 - Polymorfe former af en gabaa agonist - Google Patents

Polymorfe former af en gabaa agonist

Info

Publication number: DK1713813T3
Authority: DK; Denmark
Prior art keywords: polymorphic forms; gabaa agonist; gabaa; agonist; polymorphic
Prior art date: 2004-01-30

Application number

DK05702040T

Other languages

English (en)

Inventor

Vincent Brett Cooper

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-30

Filing date

2005-01-28

Publication date

2009-02-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1713813(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-28 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2009-02-16 Application granted granted Critical

2009-02-16 Publication of DK1713813T3 publication Critical patent/DK1713813T3/da

Links

239000000556 agonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK05702040T 2004-01-30 2005-01-28 Polymorfe former af en gabaa agonist DK1713813T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0402118.4A GB0402118D0 (en)	2004-01-30	2004-01-30	Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en)	2004-01-30	2005-01-28	Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number	Publication Date
DK1713813T3 true DK1713813T3 (da)	2009-02-16

Family

ID=31971783

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05702040T DK1713813T3 (da)	2004-01-30	2005-01-28	Polymorfe former af en gabaa agonist

Country Status (34)

Country	Link
US (2)	US7262300B2 (da)
EP (2)	EP2042505A1 (da)
JP (1)	JP4917440B2 (da)
KR (1)	KR101210361B1 (da)
CN (1)	CN1914212B (da)
AR (1)	AR047511A1 (da)
AT (1)	ATE414088T1 (da)
AU (1)	AU2005209473B2 (da)
BR (1)	BRPI0506858A (da)
CA (1)	CA2554536C (da)
CO (1)	CO5700743A2 (da)
CY (1)	CY1108647T1 (da)
DE (1)	DE602005010975D1 (da)
DK (1)	DK1713813T3 (da)
DO (1)	DOP2005000013A (da)
EA (1)	EA009413B1 (da)
EC (1)	ECSP066735A (da)
ES (1)	ES2314613T3 (da)
GB (2)	GB0402118D0 (da)
HR (1)	HRP20080614T3 (da)
IL (1)	IL176863A0 (da)
MA (1)	MA28364A1 (da)
MX (1)	MXPA06008595A (da)
MY (1)	MY139525A (da)
NO (1)	NO20063843L (da)
NZ (1)	NZ548191A (da)
PE (1)	PE20050769A1 (da)
PL (1)	PL1713813T3 (da)
PT (1)	PT1713813E (da)
SI (1)	SI1713813T1 (da)
TW (1)	TWI345972B (da)
UA (1)	UA87487C2 (da)
WO (1)	WO2005073237A2 (da)
ZA (1)	ZA200605307B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
US9072662B2 (en)	2004-03-29	2015-07-07	Auris Medical Ag	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en)	2004-03-29	2006-03-23	Matthieu Guitton	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en)	2004-03-29	2012-09-18	Matthieu Guitton	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) *	2005-01-25	2006-08-10	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Behandlung von Phantomphänomenen
EP1848420A4 (en) *	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
PT1928405E (pt)	2005-09-28	2014-10-20	Auris Medical Ag	Composições farmacêuticas para o tratamento de distúrbios do ouvido interno
CN102093387B (zh) *	2009-12-10	2012-07-25	天津泰普医药知识产权流转储备中心有限公司	4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en)	2011-12-12	2013-06-20	Auris Medical Ag	Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
KR20240160666A (ko)	2015-07-17	2024-11-11	오비드 테라퓨틱스 인크.	가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) *	2016-08-11	2023-10-11	Ovid Therapeutics, Inc.	Compositions for treatment of essential tremor
JP2019535760A (ja) *	2016-11-22	2019-12-12	オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) *	2017-02-03	2018-09-11	Ovid Therapeutics Inc	Use of gaboxadol in the treatment of tinnitus
US10813918B2 (en)	2017-08-04	2020-10-27	Ovid Therapeutics Inc.	Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en)	2018-09-20	2021-03-25	Ovid Therapeutics Inc.	Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en)	2018-11-21	2020-05-28	Certego Therapeutics	Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh)	2018-12-17	2021-09-21	奥维德医疗公司	加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
WO2021127308A1 (en)	2019-12-18	2021-06-24	Ovid Therapeutics Inc.	GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es)	2020-05-20	2022-12-16	Certego Therapeutics Inc	Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK270278A (da) *	1977-06-20	1978-12-21	Krogsgaard Larsen P	Cycliske aminosyrer
US4315934A (en) *	1979-09-24	1982-02-16	Sandoz Ltd.	Organic compounds
US4362731A (en)	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) *	1980-11-03	1982-10-05	Occidental Research Corporation	Apparatus for selective wetting of particles
DE19525598C2 (de) *	1995-07-13	1997-09-25	Max Planck Gesellschaft	Schlafmittel
UA52661C2 (uk) *	1996-06-14	2003-01-15	Ново Нордіск А/С	Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
AU7405000A (en)	1999-09-28	2001-04-30	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es)	2000-11-20	2003-09-24	Lundbeck & Co As H	Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2002094255A1 (de)	2001-05-18	2002-11-28	Lonza Ag	Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
EP1389091A1 (en)	2001-05-21	2004-02-18	H. Lundbeck A/S	Granular preparations of gaboxadol
CN100491366C (zh) *	2002-09-03	2009-05-27	华晶基因技术有限公司	汉黄芩素用作治疗焦虑症的药物的用途
US20050234093A1 (en) *	2003-06-25	2005-10-20	H. Lundbeck A/S	Treatment of depression and other affective disorders
EP1641456B1 (en) *	2003-06-25	2010-03-03	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
AR045540A1 (es)	2003-09-05	2005-11-02	Lundbeck & Co As H	Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en)	2003-09-10	2006-06-07	MERCK SHARP & DOHME LTD.	Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en)	2003-12-18	2005-09-01	Lundbeck & Co As H	Treatment of insomnia in human patients
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
AU2004324938A1 (en)	2004-06-29	2006-05-26	H. Lundbeck A/S	Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en)	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP1848420A4 (en)	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en)	2005-03-18	2007-12-12	Transform Pharmaceuticals, Inc.	Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en)	2005-04-29	2009-05-20	Lundbeck & Co As H	ACID AND BASE SALT FORMS OF GABOXADOL

2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en not_active Expired - Lifetime
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es not_active Expired - Lifetime
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en not_active Ceased
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de not_active Expired - Lifetime
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 US US11/045,768 patent/US7262300B2/en not_active Expired - Lifetime
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja not_active Expired - Lifetime
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh not_active Expired - Lifetime
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active Expired - Fee Related
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
2007
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
2008
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown

Also Published As

Publication number	Publication date
AR047511A1 (es)	2006-01-25
AU2005209473A1 (en)	2005-08-11
MA28364A1 (fr)	2006-12-01
PE20050769A1 (es)	2005-10-04
PL1713813T3 (pl)	2009-04-30
TWI345972B (en)	2011-08-01
SI1713813T1 (sl)	2009-02-28
CA2554536C (en)	2012-09-18
KR20070007070A (ko)	2007-01-12
US7262300B2 (en)	2007-08-28
NZ548191A (en)	2010-04-30
EA009413B1 (ru)	2007-12-28
US20050171142A1 (en)	2005-08-04
DOP2005000013A (es)	2005-08-15
DE602005010975D1 (de)	2008-12-24
CN1914212A (zh)	2007-02-14
JP2007519697A (ja)	2007-07-19
JP4917440B2 (ja)	2012-04-18
CO5700743A2 (es)	2006-11-30
UA87487C2 (ru)	2009-07-27
WO2005073237A2 (en)	2005-08-11
US8236958B2 (en)	2012-08-07
CA2554536A1 (en)	2005-08-11
WO2005073237A3 (en)	2005-10-20
MXPA06008595A (es)	2006-08-28
ES2314613T3 (es)	2009-03-16
ATE414088T1 (de)	2008-11-15
EP2042505A1 (en)	2009-04-01
GB0501847D0 (en)	2005-03-09
NO20063843L (no)	2006-08-29
EA200601404A1 (ru)	2006-12-29
TW200534856A (en)	2005-11-01
BRPI0506858A (pt)	2007-05-29
HK1096547A1 (en)	2007-06-01
ZA200605307B (en)	2007-11-28
GB0402118D0 (en)	2004-03-03
ECSP066735A (es)	2006-10-31
EP1713813B1 (en)	2008-11-12
KR101210361B1 (ko)	2012-12-10
EP1713813A2 (en)	2006-10-25
PT1713813E (pt)	2008-12-26
US20070259912A1 (en)	2007-11-08
IL176863A0 (en)	2006-10-31
MY139525A (en)	2009-10-30
CY1108647T1 (el)	2014-04-09
HRP20080614T3 (en)	2009-01-31
CN1914212B (zh)	2010-10-06
AU2005209473B2 (en)	2010-03-04
GB2410434A (en)	2005-08-03

Publication	Publication Date	Title
DK2064189T3 (da)	2012-01-02	Polymorfe former af 4-[3-(4-cyklopropancarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phathalazin-1-on
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
BRPI0806945A2 (pt)	2014-05-06	Formas polimórficas de um inibidor macrocíclico de hcv
DK2423325T3 (da)	2019-06-24	Fremgangsmåde til fremstilling af biblioteker af template-polynukleotider
DK1778672T3 (da)	2013-03-25	Krystallinsk form af en biphenylforbindelse
DK1856050T3 (da)	2010-02-01	Krystallinske former af en biphenylforbindelse
DK1737461T3 (da)	2013-03-18	Carbolin-derivater til inhibering af angiogenese
EP1948569A4 (en)	2013-01-09	DRAINING FULL SLUDGE
DK2117542T3 (da)	2011-10-31	Kombinationer af beta-2-adrenoceptor-agonistisk benzothiazolon
DK2126801T3 (da)	2013-06-24	Fremgangsmåde til udvælgelse af information
DK2127449T3 (da)	2014-09-22	Tidsplanlægning af en dynamisk radiokanal
DK2073636T3 (da)	2012-11-19	Fremgangsmåde til fremstilling af oxymorphon
DK1963302T3 (da)	2013-04-02	Polymorfer af en C-MET/HGFR-inhibitor
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi
TWI345972B (en)	2011-08-01	Polymorphic forms of a gabaa agonist
DK2235046T3 (da)	2012-10-29	Mutante former af streptolysin-O
DK2402005T3 (da)	2021-03-15	Formuleringer med langvarig frigivelse af nalbuphin
DK2083629T3 (da)	2011-09-26	Krystallinsk modifikation af fipronil
DK2019118T3 (da)	2013-02-04	Fremgangsmåde til syntetisering af thymosiner
DK2021309T3 (da)	2014-07-21	Fremgangsmåde til fremstilling af methanol
DK1917253T3 (da)	2015-03-30	Fremgangsmåde til fremstilling af betamimetika
DK2371818T3 (da)	2013-03-25	Hydroxybenzoatsalte af metanikotinforbindelser
DK1874766T3 (da)	2010-12-06	Krystallinsk form af en quinolinon-carboxamid-forbindelse
DK1825484T3 (da)	2019-11-11	Fremgangsmåde til fremstilling af kabler
DK1667975T3 (da)	2008-04-14	En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin